Literature DB >> 10197964

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.

P S Dragovich1, T J Prins, R Zhou, S A Fuhrman, A K Patick, D A Matthews, C E Ford, J W Meador, R A Ferre, S T Worland.   

Abstract

The structure-based design, chemical synthesis, and biological evaluation of various ketomethylene-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and an ethyl propenoate Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The ketomethylene-containing inhibitors typically display slightly reduced 3CP inhibition activity relative to the corresponding peptide-derived molecules, but they also exhibit significantly improved antiviral properties. Optimization of the ketomethylene-containing compounds is shown to provide several highly active 3C protease inhibitors which function as potent antirhinoviral agents (EC90 = <1 microM) against multiple virus serotypes in cell culture.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10197964     DOI: 10.1021/jm980537b

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

1.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Authors:  D A Matthews; P S Dragovich; S E Webber; S A Fuhrman; A K Patick; L S Zalman; T F Hendrickson; R A Love; T J Prins; J T Marakovits; R Zhou; J Tikhe; C E Ford; J W Meador; R A Ferre; E L Brown; S L Binford; M A Brothers; D M DeLisle; S T Worland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir.

Authors:  Céline Lacroix; Shyla George; Pieter Leyssen; Rolf Hilgenfeld; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

3.  Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor.

Authors:  L S Zalman; M A Brothers; P S Dragovich; R Zhou; T J Prins; S T Worland; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

Authors:  A K Patick; S L Binford; M A Brothers; R L Jackson; C E Ford; M D Diem; F Maldonado; P S Dragovich; R Zhou; T J Prins; S A Fuhrman; J W Meador; L S Zalman; D A Matthews; S T Worland
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

5.  Structure of the HRV-C 3C-Rupintrivir Complex Provides New Insights for Inhibitor Design.

Authors:  Shuai Yuan; Kaiyue Fan; Zhonghao Chen; Yao Sun; Hai Hou; Ling Zhu
Journal:  Virol Sin       Date:  2020-02-26       Impact factor: 4.327

6.  Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.

Authors:  S L Binford; F Maldonado; M A Brothers; P T Weady; L S Zalman; J W Meador; D A Matthews; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

7.  High-throughput screening identifies three inhibitor classes of the telomere resolvase from the lyme disease spirochete.

Authors:  Georgia Lefas; George Chaconas
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

Review 8.  Current research on respiratory viral infections: Fourth International Symposium.

Authors:  Michael G Ison; John Mills; Peter Openshaw; Maria Zambon; Albert Osterhaus; Frederick Hayden
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

9.  Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses.

Authors:  Yunjeong Kim; Scott Lovell; Kok-Chuan Tiew; Sivakoteswara Rao Mandadapu; Kevin R Alliston; Kevin P Battaile; William C Groutas; Kyeong-Ok Chang
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

10.  Current research on respiratory viral infections: Fifth International Symposium.

Authors:  Michael G Ison; Sebastian L Johnston; Peter Openshaw; Brian Murphy; Frederick Hayden
Journal:  Antiviral Res       Date:  2004-06       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.